Related Experiment Videos
Achieving LDL-C target levels: the role of statins
1Service de Cardiologie B et Hemodynamique, Hôpital Cardiologique, 59037 Lille, France. jmlablanche@chru-lille.fr
Insights
Many patients struggle to reach target low-density lipoprotein cholesterol (LDL-C) levels, crucial for preventing coronary heart disease (CHD). Utilizing more potent statins or higher doses can help more individuals achieve these vital lipid-lowering goals.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Public Health
Background:
- Elevated low-density lipoprotein cholesterol (LDL-C) is a well-established risk factor for coronary heart disease (CHD).
- Current treatment guidelines identify LDL-C as a primary target for lipid-lowering therapies.
- Statins (HMG-CoA reductase inhibitors) are the primary pharmacologic agents for LDL-C reduction.
Purpose of the Study:
- To evaluate the effectiveness of statins in achieving recommended LDL-C target levels in patients.
- To identify factors contributing to the failure in reaching LDL-C goals.
- To explore strategies for improving LDL-C target attainment, particularly in high-risk populations.
Main Methods:
- Review of epidemiological and clinical studies on LDL-C and CHD.
- Analysis of treatment guidelines and current therapeutic practices.
- Examination of survey data on patient achievement of LDL-C targets.
Main Results:
- Despite statin efficacy, a significant number of patients do not reach their LDL-C targets.
- Inadequate drug selection and dosage are common issues contributing to treatment failure.
- Patients with established CHD, the highest-risk group, show the lowest success rates in achieving LDL-C goals.
Conclusions:
- More aggressive lipid-lowering strategies are needed to improve LDL-C target attainment.
- The use of more potent statins or higher doses of existing statins should be considered.
- Optimizing statin therapy is essential for reducing cardiovascular risk, especially in high-risk patients.
Abstract:
Epidemiological and clinical studies have clearly established the link between elevated low-density lipoprotein cholesterol (LDL-C) and coronary heart disease (CHD). Consequently, treatment guidelines have been developed that identify LDL-C as a causative factor for CHD and as a target for lipid-lowering therapy. The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are considered the drugs of choice for lowering LDL-C in patients with hypercholesterolaemia. However, despite the proven efficacy of statins in reducing LDL-C, many patients do not achieve recommended LDL-C target levels. Surveys suggest that patients do not receive the appropriate drugs in adequate dosage to reach LDL-C target values. Success in achieving targets is lowest in patients at the highest risk, i.e. those with established CHD. The introduction of more potent HMG-CoA reductase inhibitors, or the use of higher doses of older statins, should allow more patients to achieve LDL-C target levels.